Table 2.

Genetically modified, expanded allogeneic NK cells.

Modification	Genes transferred	NK cells	Application	Status	Reference/ClinicalTrials.gov Identifier
Target specificity	CD19	Haploidentical, expanded NK cells	ALL	Phase 1	St. Jude Children’s Research Hospital (NCT00995137)
	CD19	Haploidentical, expanded NK cells	ALL	Phase 2	National University Health System, Singapore (NCT01974479)
	CD19	Expanded NK cells	B-ALL	Preclinical	Cho et al. (52)
	CD20	Expanded NK cells	CD20+ B-NHL	Preclinical	Chu et al. (53)
	GD2	Expanded NK cells	Neuroblastoma	Preclinical	Esser et al. (54)
NK cell function	NKG2D	Expanded NK cells	Various tumor targets (B-ALL etc.)	Preclinical	Chang et al. (55)
	IL-12	IL-2-activated NK cells	B16 lung tumor	Preclinical	Goding et al. (56)

ALL, acute lymphocytic leukemia; B-NHL, B-cell non-Hodgkin lymphoma; B-ALL, B-cell acute lymphoblastic leukemia.